The three effective, commercially available drugs for the treatment of erectile dysfunction-sildenafil, vardenafil, and tadalafil-inhibit the same substrate, the erectolytic enzyme phosphodiesterase type 5 (PDE5). Although there are pharmacological differences between these three compounds, few comparative studies have been conducted to date.
Jannini, E., Isidori, A., Gravina, G., Aversa, A., Balercia, G., Bocchio, M., et al. (2009). The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction. JOURNAL OF SEXUAL MEDICINE, 6(9), 2547-2560 [10.1111/j.1743-6109.2009.01375.x].
The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction
JANNINI, EMMANUELE ANGELO FRANCESCO;FABBRI, ANDREA;
2009-01-01
Abstract
The three effective, commercially available drugs for the treatment of erectile dysfunction-sildenafil, vardenafil, and tadalafil-inhibit the same substrate, the erectolytic enzyme phosphodiesterase type 5 (PDE5). Although there are pharmacological differences between these three compounds, few comparative studies have been conducted to date.| File | Dimensione | Formato | |
|---|---|---|---|
|
jsm endotrial.pdf
solo utenti autorizzati
Descrizione: Articolo principale
Licenza:
Copyright dell'editore
Dimensione
202.91 kB
Formato
Adobe PDF
|
202.91 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
